SpyGlass Pharma's total assets for Q1 2026 were $258.39M, an increase of 123.00% from the previous quarter. SGP total liabilities were $8.27M for the fiscal quarter, a -96.15% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.
